Daniel R. Alonso extensively quoted in Anti-Corruption Report article, “Novartis and subsidiaries settle FCPA cases for $346M, avoiding a monitor despite recidivism”
Anti-Corruption ReportDaniel R. Alonso
Daniel R. Alonso was extensively quoted on July 8, 2020 in an Anti-Corruption Report article, “Novartis and subsidiaries settle FCPA cases for $346M, avoiding a monitor despite recidivism,” which discussed Swiss pharmaceutical and healthcare company Novartis AG and its subsidiaries’ $346 million settlement with the U.S. Department of Justice for its alleged FCPA charges, and how the company avoided a monitorship.
Alonso noted, “Ordinarily, when one hears of recidivism within a company, it suggests that the compliance culture within the company is deficient. But it also seems in this case that the DOJ was thoroughly impressed with the measures Novartis undertook to beef up its compliance in the wake of the allegations. Ultimately, the DOJ appears to have concluded that Novartis’s compliance program in 2020 obviated the need for a costly, multi-year monitorship."
Click here to read the full article. Subscription required.